Faculty

Back to Index
Brad Spellberg, MD
Professor of Clinical Medicine
Associate Dean For Clinical Affairs (LAC+USC)
Medicine
KEK 1500 San Pablo St Health Sciences Campus Los Angeles

Overview

Dr. Spellberg is Chief Medical Officer at the Los Angeles County-University of Southern California (LAC+USC) Medical Center. He is also a Professor of Clinical Medicine and Associate Dean for Clinical Affairs at the Keck School of Medicine at USC. He received his BA in Molecular Cell Biology-Immunology from UC Berkeley. He then attended medical school at UCLA, where he received numerous academic honors, including serving as the UCLA AOA Chapter Co-President, and winning the prestigious Stafford Warren Award for the topic academic performance in his graduating class. Dr. Spellberg completed his Residency in Internal Medicine and subspecialty fellowship in Infectious Diseases at Harbor-UCLA Medical Center.

Dr. Spellberg has extensive administrative, patient care, and teaching activities. His NIH-funded research interests are diverse, ranging from basic immunology and vaccinology, to pure clinical and outcomes research, to process improvement work related to delivery of care, focusing on safety net hospitals. His laboratory research has focused on developing a vaccine that targets the bacterium Staphylococcus aureus and the fungus Candida; the vaccine is undergoing clinical development. Dr. Spellberg is currently working on the immunology, vaccinology, and host defense against highly resistant Gram negative bacilli, including Acinetobacter and carbapenem-resistant Enterobacteriaceae infections.

Dr. Spellberg has worked extensively with the Infectious Diseases Society of America (IDSA) to attempt to bring attention to the problems of increasing drug resistance and decreasing new antibiotics. His research regarding new drug development was a cornerstone of the IDSA’s white paper, Bad Bugs, No Drugs, and has been cited extensively in medical literature and on Capitol Hill. He first-authored numerous societal position papers and review articles relating to public policy of antibiotic resistance and antibiotic development. Dr. Spellberg is the author of Rising Plague, which he wrote to inform and educate the public about the crisis in antibiotic resistant infections and lack of antibiotic development. He has appeared on TV programs including Dr. Oz, The Doctors, Katie Couric, and has given numerous radio and news interviews.

Outside of medicine, he enjoys intergalactic hyperspace travel, dinosaur cloning, and going after bad guys while dressed up in a Kevlar suit with a cool utility belt. He has also been known to split an atom or two from time to time when bored. Sometimes, he reads non-medical textbooks and lifts weights.

Awards

Choice Magazine: Outstanding Academic Title Award for Rising Plague, 2010

UCLA School of Medicine: First STAR Summer Fellowship Award, 1996

UCLA Alpha Omega Alpha: Chapter Co-President, 1998-1999

Alpha Omega Alpha: Elected Member, 1998

Department of Medicine, UCLA: Kouichi R. Tanaka Distinguished Faculty Teaching Award, 2011

UCLA Department of Medicine: Faculty Award for Outstanding Junior Medicine Clerk, 1999

University of California, Berkeley: Summa Cum Laude, 1994

American College of Physicians: Outstanding Student in Internal Medicine at UCLA, 1999

Harbor-UCLA Medical Center: Subspecialty Fellow of the Year, 2004

Phi Beta Kappa: Elected Member, 1994

LA Biomedical Research Institute : Liu Young Investigator's Award, 2007

University of California, Berkeley: Dean's List, 1991-1994

UCLA School of Medicine: Stafford Warren Award, 1999

LA BioMed Research Institute: Richard E. Weitzman Memorial Prize for Meritorious Research, 2013

UCLA School of Medicine: ORNG Application Instance for Person, 1996

American College of Physicians: ORNG Application Instance for Person, 1999

UCLA Department of Medicine: ORNG Application Instance for Person, 1999

Phi Beta Kappa: ORNG Application Instance for Person, 1994

UCLA School of Medicine: ORNG Application Instance for Person, 1999

Alpha Omega Alpha: ORNG Application Instance for Person, 1998

University of California, Berkeley: ORNG Application Instance for Person, 1994

Harbor-UCLA Medical Center: ORNG Application Instance for Person, 2004

LA BioMed Research Institute: ORNG Application Instance for Person, 2013

Department of Medicine, UCLA: ORNG Application Instance for Person, 2011

University of California, Berkeley: ORNG Application Instance for Person, 1991-1994

Choice Magazine: ORNG Application Instance for Person, 2010

UCLA Alpha Omega Alpha: ORNG Application Instance for Person, 1998-1999

UCLA Department of Medicine: full name, 1999

Choice Magazine: full name, 2010

UCLA School of Medicine: full name, 1996

Harbor-UCLA Medical Center: full name, 2004

UCLA School of Medicine: full name, 1999

Phi Beta Kappa: full name, 1994

UCLA Alpha Omega Alpha: full name, 1998-1999

Alpha Omega Alpha: full name, 1998

University of California, Berkeley: full name, 1991-1994

LA Biomedical Research Institute : full name, 2007

University of California, Berkeley: full name, 1994

Department of Medicine, UCLA: full name, 2011

LA BioMed Research Institute: full name, 2013

American College of Physicians: full name, 1999

UCLA Department of Medicine: person in primary position, 1999

LA Biomedical Research Institute : person in primary position, 2007

Alpha Omega Alpha: person in primary position, 1998

UCLA School of Medicine: person in primary position, 1999

Choice Magazine: person in primary position, 2010

American College of Physicians: person in primary position, 1999

University of California, Berkeley: person in primary position, 1991-1994

LA BioMed Research Institute: person in primary position, 2013

Department of Medicine, UCLA: person in primary position, 2011

Harbor-UCLA Medical Center: person in primary position, 2004

University of California, Berkeley: person in primary position, 1994

UCLA School of Medicine: person in primary position, 1996

Phi Beta Kappa: person in primary position, 1994

Department of Medicine, UCLA: last name, 2011

UCLA Alpha Omega Alpha: last name, 1998-1999

UCLA School of Medicine: last name, 1999

Alpha Omega Alpha: last name, 1998

American College of Physicians: last name, 1999

UCLA School of Medicine: last name, 1996

LA Biomedical Research Institute : last name, 2007

University of California, Berkeley: last name, 1994

Phi Beta Kappa: last name, 1994

University of California, Berkeley: last name, 1991-1994

Choice Magazine: last name, 2010

LA BioMed Research Institute: last name, 2013

Harbor-UCLA Medical Center: last name, 2004

UCLA Department of Medicine: last name, 1999

University of California, Berkeley: In The News, 1994

American College of Physicians: In The News, 1999

University of California, Berkeley: In The News, 1991-1994

UCLA Alpha Omega Alpha: In The News, 1998-1999

Alpha Omega Alpha: In The News, 1998

LA BioMed Research Institute: In The News, 2013

UCLA Department of Medicine: In The News, 1999

LA Biomedical Research Institute : In The News, 2007

UCLA School of Medicine: In The News, 1996

Choice Magazine: In The News, 2010

Harbor-UCLA Medical Center: In The News, 2004

Phi Beta Kappa: In The News, 1994

UCLA School of Medicine: In The News, 1999

UCLA School of Medicine: ORNG Application URL, 1999

University of California, Berkeley: ORNG Application URL, 1991-1994

Phi Beta Kappa: ORNG Application URL, 1994

American College of Physicians: ORNG Application URL, 1999

LA Biomedical Research Institute : ORNG Application URL, 2007

UCLA Department of Medicine: ORNG Application URL, 1999

Choice Magazine: ORNG Application URL, 2010

UCLA Alpha Omega Alpha: ORNG Application URL, 1998-1999

Alpha Omega Alpha: ORNG Application URL, 1998

University of California, Berkeley: ORNG Application URL, 1994

UCLA School of Medicine: ORNG Application URL, 1996

Harbor-UCLA Medical Center: ORNG Application URL, 2004

Department of Medicine, UCLA: ORNG Application URL, 2011

LA BioMed Research Institute: ORNG Application URL, 2013

UCLA School of Medicine: sort order, 1999

Choice Magazine: sort order, 2010

LA Biomedical Research Institute : sort order, 2007

Phi Beta Kappa: sort order, 1994

University of California, Berkeley: sort order, 1991-1994

Harbor-UCLA Medical Center: sort order, 2004

UCLA School of Medicine: sort order, 1996

American College of Physicians: sort order, 1999

Alpha Omega Alpha: sort order, 1998

University of California, Berkeley: sort order, 1994

LA BioMed Research Institute: sort order, 2013

UCLA Alpha Omega Alpha: sort order, 1998-1999

Department of Medicine, UCLA: Organization, 2011

University of California, Berkeley: Organization, 1991-1994

University of California, Berkeley: Organization, 1994

UCLA School of Medicine: Organization, 1996

Alpha Omega Alpha: Organization, 1998

UCLA School of Medicine: Organization, 1999

Harbor-UCLA Medical Center: Organization, 2004

UCLA Alpha Omega Alpha: Organization, 1998-1999

Choice Magazine: Organization, 2010

Phi Beta Kappa: Organization, 1994

LA BioMed Research Institute: Organization, 2013

UCLA Department of Medicine: Organization, 1999

LA Biomedical Research Institute : Organization, 2007

American College of Physicians: Organization, 1999

UCLA School of Medicine: email address, 1996

University of California, Berkeley: email address, 1991-1994

Department of Medicine, UCLA: email address, 2011

UCLA Alpha Omega Alpha: email address, 1998-1999

Choice Magazine: email address, 2010

University of California, Berkeley: email address, 1994

UCLA School of Medicine: email address, 1999

Alpha Omega Alpha: email address, 1998

Phi Beta Kappa: email address, 1994

LA BioMed Research Institute: email address, 2013

Harbor-UCLA Medical Center: email address, 2004

LA Biomedical Research Institute : email address, 2007

American College of Physicians: email address, 1999

University of California, Berkeley: start date, 1991-1994

Alpha Omega Alpha: start date, 1998

American College of Physicians: start date, 1999

LA BioMed Research Institute: start date, 2013

Department of Medicine, UCLA: start date, 2011

LA Biomedical Research Institute : start date, 2007

UCLA Department of Medicine: start date, 1999

Phi Beta Kappa: start date, 1994

UCLA Alpha Omega Alpha: start date, 1998-1999

UCLA School of Medicine: start date, 1996

University of California, Berkeley: start date, 1994

Harbor-UCLA Medical Center: start date, 2004

UCLA School of Medicine: start date, 1999

Choice Magazine: start date, 2010

Harbor-UCLA Medical Center: has ORNG Application Instance Data, 2004

University of California, Berkeley: has ORNG Application Instance Data, 1994

Phi Beta Kappa: has ORNG Application Instance Data, 1994

Choice Magazine: has ORNG Application Instance Data, 2010

UCLA School of Medicine: has ORNG Application Instance Data, 1999

LA Biomedical Research Institute : has ORNG Application Instance Data, 2007

UCLA Alpha Omega Alpha: has ORNG Application Instance Data, 1998-1999

Alpha Omega Alpha: has ORNG Application Instance Data, 1998

UCLA Department of Medicine: has ORNG Application Instance Data, 1999

University of California, Berkeley: has ORNG Application Instance Data, 1991-1994

Department of Medicine, UCLA: has ORNG Application Instance Data, 2011

LA BioMed Research Institute: has ORNG Application Instance Data, 2013

American College of Physicians: has ORNG Application Instance Data, 1999

LA Biomedical Research Institute : MediaLinks, 2007

UCLA Alpha Omega Alpha: end date, 1998-1999

University of California, Berkeley: MediaLinks, 1994

University of California, Berkeley: end date, 1991-1994

Choice Magazine: MediaLinks, 2010

Department of Medicine, UCLA: MediaLinks, 2011

Alpha Omega Alpha: MediaLinks, 1998

UCLA Department of Medicine: MediaLinks, 1999

American College of Physicians: MediaLinks, 1999

UCLA School of Medicine: MediaLinks, 1996

Phi Beta Kappa: MediaLinks, 1994

UCLA School of Medicine: MediaLinks, 1999

LA BioMed Research Institute: MediaLinks, 2013

Harbor-UCLA Medical Center: MediaLinks, 2004

LA BioMed Research Institute: Associate Professor, 2013

UCLA School of Medicine: Associate Professor, 1999

Phi Beta Kappa: Associate Professor, 1994

Harbor-UCLA Medical Center: Associate Professor, 2004

Department of Medicine, UCLA: Associate Professor, 2011

University of California, Berkeley: Associate Professor, 1994

University of California, Berkeley: Associate Professor, 1991-1994

UCLA Department of Medicine: Associate Professor, 1999

UCLA School of Medicine: Associate Professor, 1996

UCLA Alpha Omega Alpha: Associate Professor, 1998-1999

American College of Physicians: Associate Professor, 1999

LA Biomedical Research Institute : Associate Professor, 2007

Choice Magazine: Associate Professor, 2010

Phi Beta Kappa: label, 1994

UCLA Alpha Omega Alpha: label, 1998-1999

University of California, Berkeley: label, 1994

Harbor-UCLA Medical Center: label, 2004

University of California, Berkeley: label, 1991-1994

LA BioMed Research Institute: label, 2013

Alpha Omega Alpha: label, 1998

Choice Magazine: label, 2010

LA Biomedical Research Institute : label, 2007

UCLA Department of Medicine: label, 1999

UCLA School of Medicine: label, 1996

American College of Physicians: label, 1999

UCLA School of Medicine: label, 1999

Harbor-UCLA Medical Center: award conferred by, 2004

UCLA Department of Medicine: award conferred by, 1999

University of California, Berkeley: award conferred by, 1994

Phi Beta Kappa: award conferred by, 1994

Choice Magazine: award conferred by, 2010

UCLA School of Medicine: award conferred by, 1996

University of California, Berkeley: award conferred by, 1991-1994

Alpha Omega Alpha: award conferred by, 1998

Department of Medicine, UCLA: award conferred by, 2011

UCLA Alpha Omega Alpha: award conferred by, 1998-1999

American College of Physicians: award conferred by, 1999

LA BioMed Research Institute: award conferred by, 2013

LA Biomedical Research Institute : award conferred by, 2007

UCLA School of Medicine: award conferred by, 1999

Phi Beta Kappa: Faculty Rank, 1994

UCLA School of Medicine: Faculty Rank, 1999

UCLA School of Medicine: Faculty Rank, 1996

UCLA Alpha Omega Alpha: Faculty Rank, 1998-1999

Choice Magazine: Faculty Rank, 2010

University of California, Berkeley: Faculty Rank, 1994

University of California, Berkeley: Faculty Rank, 1991-1994

LA BioMed Research Institute: Faculty Rank, 2013

UCLA Department of Medicine: Faculty Rank, 1999

American College of Physicians: Faculty Rank, 1999

Department of Medicine, UCLA: Faculty Rank, 2011

Alpha Omega Alpha: Faculty Rank, 1998

LA Biomedical Research Institute : Faculty Rank, 2007

Harbor-UCLA Medical Center: Faculty Rank, 2004

Harbor-UCLA Medical Center: is primary position, 2004

American College of Physicians: is primary position, 1999

University of California, Berkeley: is primary position, 1994

Phi Beta Kappa: is primary position, 1994

Department of Medicine, UCLA: is primary position, 2011

Choice Magazine: is primary position, 2010

UCLA School of Medicine: is primary position, 1999

Alpha Omega Alpha: is primary position, 1998

University of California, Berkeley: is primary position, 1991-1994

UCLA Alpha Omega Alpha: is primary position, 1998-1999

UCLA School of Medicine: is primary position, 1996

LA Biomedical Research Institute : is primary position, 2007

LA BioMed Research Institute: is primary position, 2013

UCLA Department of Medicine: is primary position, 1999

UCLA Alpha Omega Alpha: person in primary position, 1998-1999

LA BioMed Research Institute: Spellberg, Brad, 2013

Department of Medicine, UCLA: Spellberg, Brad, 2011

University of California, Berkeley: Spellberg, Brad, 1994

American College of Physicians: Spellberg, Brad, 1999

UCLA School of Medicine: Spellberg, Brad, 1999

Alpha Omega Alpha: Spellberg, Brad, 1998

UCLA School of Medicine: Spellberg, Brad, 1996

UCLA Alpha Omega Alpha: Spellberg, Brad, 1998-1999

University of California, Berkeley: Spellberg, Brad, 1991-1994

Phi Beta Kappa: Spellberg, Brad, 1994

LA Biomedical Research Institute : Spellberg, Brad, 2007

Harbor-UCLA Medical Center: Spellberg, Brad, 2004

UCLA Department of Medicine: Spellberg, Brad, 1999

Choice Magazine: Spellberg, Brad, 2010

UCLA Alpha Omega Alpha: links, 1998-1999

Harbor-UCLA Medical Center: links, 2004

Alpha Omega Alpha: links, 1998

LA BioMed Research Institute: links, 2013

Choice Magazine: links, 2010

UCLA School of Medicine: links, 1999

UCLA School of Medicine: links, 1996

University of California, Berkeley: links, 1991-1994

University of California, Berkeley: links, 1994

LA Biomedical Research Institute : links, 2007

American College of Physicians: links, 1999

UCLA Department of Medicine: links, 1999

Department of Medicine, UCLA: links, 2011

LA Biomedical Research Institute : ORNG Application Instance for Person, 2007

UCLA School of Medicine: has ORNG Application Instance Data, 1996

Choice Magazine: position in organization, 2010

American College of Physicians: position in organization, 1999

Harbor-UCLA Medical Center: position in organization, 2004

Alpha Omega Alpha: position in organization, 1998

UCLA Department of Medicine: position in organization, 1999

University of California, Berkeley: position in organization, 1991-1994

UCLA Alpha Omega Alpha: position in organization, 1998-1999

UCLA School of Medicine: position in organization, 1999

UCLA School of Medicine: position in organization, 1996

Department of Medicine, UCLA: position in organization, 2011

LA BioMed Research Institute: position in organization, 2013

LA Biomedical Research Institute : position in organization, 2007

UCLA Department of Medicine: email address, 1999

Phi Beta Kappa: links, 1994

Alpha Omega Alpha: Associate Professor, 1998

Harbor-UCLA Medical Center: ORNG Application Instance Data value, 2004

American College of Physicians: ORNG Application Instance Data value, 1999

UCLA School of Medicine: ORNG Application Instance Data value, 1996

UCLA School of Medicine: ORNG Application Instance Data value, 1999

UCLA Department of Medicine: ORNG Application Instance Data value, 1999

University of California, Berkeley: ORNG Application Instance Data value, 1991-1994

LA BioMed Research Institute: ORNG Application Instance Data value, 2013

Phi Beta Kappa: ORNG Application Instance Data value, 1994

Alpha Omega Alpha: ORNG Application Instance Data value, 1998

Choice Magazine: ORNG Application Instance Data value, 2010

University of California, Berkeley: ORNG Application Instance Data value, 1994

Department of Medicine, UCLA: ORNG Application Instance Data value, 2011

UCLA Alpha Omega Alpha: ORNG Application Instance Data value, 1998-1999

LA Biomedical Research Institute : Keck School of Medicine of USC, 2007

American College of Physicians: Keck School of Medicine of USC, 1999

University of California, Berkeley: Keck School of Medicine of USC, 1991-1994

Phi Beta Kappa: Keck School of Medicine of USC, 1994

UCLA School of Medicine: Keck School of Medicine of USC, 1996

UCLA School of Medicine: Keck School of Medicine of USC, 1999

UCLA Alpha Omega Alpha: Keck School of Medicine of USC, 1998-1999

University of California, Berkeley: Keck School of Medicine of USC, 1994

LA BioMed Research Institute: Keck School of Medicine of USC, 2013

Harbor-UCLA Medical Center: Keck School of Medicine of USC, 2004

Department of Medicine, UCLA: Keck School of Medicine of USC, 2011

Choice Magazine: Keck School of Medicine of USC, 2010

Alpha Omega Alpha: Keck School of Medicine of USC, 1998

UCLA Department of Medicine: Keck School of Medicine of USC, 1999

University of California, Berkeley: MediaLinks, 1991-1994

UCLA Alpha Omega Alpha: MediaLinks, 1998-1999

Alpha Omega Alpha: Position, 1998

UCLA Alpha Omega Alpha: Position, 1998-1999

Phi Beta Kappa: Position, 1994

American College of Physicians: Position, 1999

LA Biomedical Research Institute : Position, 2007

UCLA Department of Medicine: Position, 1999

Choice Magazine: Position, 2010

University of California, Berkeley: Position, 1994

UCLA School of Medicine: Position, 1996

UCLA School of Medicine: Position, 1999

University of California, Berkeley: Position, 1991-1994

Department of Medicine, UCLA: Position, 2011

LA BioMed Research Institute: Position, 2013

Harbor-UCLA Medical Center: Position, 2004

LA Biomedical Research Institute : ORNG Application Instance Data value, 2007

LA Biomedical Research Institute : HR job title, 2007

Alpha Omega Alpha: HR job title, 1998

UCLA Department of Medicine: HR job title, 1999

UCLA Alpha Omega Alpha: HR job title, 1998-1999

UCLA School of Medicine: HR job title, 1996

University of California, Berkeley: HR job title, 1994

American College of Physicians: HR job title, 1999

Phi Beta Kappa: HR job title, 1994

Department of Medicine, UCLA: HR job title, 2011

University of California, Berkeley: HR job title, 1991-1994

UCLA School of Medicine: HR job title, 1999

Choice Magazine: HR job title, 2010

Harbor-UCLA Medical Center: HR job title, 2004

LA BioMed Research Institute: HR job title, 2013

UCLA School of Medicine: first name, 1996

UCLA School of Medicine: first name, 1999

LA Biomedical Research Institute : first name, 2007

University of California, Berkeley: first name, 1994

American College of Physicians: first name, 1999

Department of Medicine, UCLA: first name, 2011

Alpha Omega Alpha: first name, 1998

Harbor-UCLA Medical Center: first name, 2004

Phi Beta Kappa: first name, 1994

UCLA Department of Medicine: first name, 1999

Choice Magazine: first name, 2010

LA BioMed Research Institute: first name, 2013

UCLA Department of Medicine: has faculty rank, 1999

Alpha Omega Alpha: has faculty rank, 1998

Phi Beta Kappa: has faculty rank, 1994

UCLA School of Medicine: has faculty rank, 1996

University of California, Berkeley: has faculty rank, 1994

American College of Physicians: has faculty rank, 1999

UCLA School of Medicine: has faculty rank, 1999

Department of Medicine, UCLA: has faculty rank, 2011

Harbor-UCLA Medical Center: has faculty rank, 2004

University of California, Berkeley: has faculty rank, 1991-1994

LA Biomedical Research Institute : has faculty rank, 2007

Choice Magazine: has faculty rank, 2010

LA BioMed Research Institute: has faculty rank, 2013

UCLA Alpha Omega Alpha: has faculty rank, 1998-1999

UCLA School of Medicine: ORNG Application Instance of Application, 1996

Choice Magazine: ORNG Application Instance of Application, 2010

UCLA Alpha Omega Alpha: ORNG Application Instance of Application, 1998-1999

University of California, Berkeley: ORNG Application Instance of Application, 1994

Harbor-UCLA Medical Center: ORNG Application Instance of Application, 2004

UCLA Department of Medicine: ORNG Application Instance of Application, 1999

University of California, Berkeley: ORNG Application Instance of Application, 1991-1994

American College of Physicians: ORNG Application Instance of Application, 1999

UCLA School of Medicine: ORNG Application Instance of Application, 1999

Department of Medicine, UCLA: ORNG Application Instance of Application, 2011

Phi Beta Kappa: ORNG Application Instance of Application, 1994

LA BioMed Research Institute: ORNG Application Instance of Application, 2013

Alpha Omega Alpha: ORNG Application Instance of Application, 1998

UCLA Alpha Omega Alpha: Medicine, 1998-1999

Department of Medicine, UCLA: Medicine, 2011

LA BioMed Research Institute: Medicine, 2013

University of California, Berkeley: Medicine, 1991-1994

UCLA Department of Medicine: Medicine, 1999

UCLA School of Medicine: Medicine, 1999

American College of Physicians: Medicine, 1999

Harbor-UCLA Medical Center: Medicine, 2004

University of California, Berkeley: Medicine, 1994

Phi Beta Kappa: Medicine, 1994

LA Biomedical Research Institute : Medicine, 2007

UCLA School of Medicine: Medicine, 1996

Alpha Omega Alpha: Medicine, 1998

Choice Magazine: Medicine, 2010

Department of Medicine, UCLA: label, 2011

Publications

Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev. 2017 Jan; 30(1):409-447. View in: PubMed

Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat". Clin Infect Dis. 2016 Dec 15; 63(12):1619-1621. View in: PubMed

Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good. Clin Pharmacol Ther. 2016 Dec; 100(6):597-599. View in: PubMed

How to Pitch an Antibiotic Stewardship Program to the Hospital C-Suite. Open Forum Infect Dis. 2016 Oct; 3(4):ofw210. View in: PubMed

Debunking the July Effect Myth. J Patient Saf. 2016 Sep 08. View in: PubMed

The New Antibiotic Mantra-"Shorter Is Better". JAMA Intern Med. 2016 Sep 1; 176(9):1254-5. View in: PubMed

The VITAL study: case control studies are hypothesis-generating. Lancet Infect Dis. 2016 Aug; 16(8):886. View in: PubMed

Trimethoprim-Sulfamethoxazole for Uncomplicated Skin Abscess. N Engl J Med. 2016 Jul 21; 375(3):284-6. View in: PubMed

Leveraging Antimicrobial Stewardship into Improving Rates of Carbapenem-Resistant Enterobacteriaceae. Virulence. 2016 May 17; 0. View in: PubMed

New Societal Approaches to Empowering Antibiotic Stewardship. JAMA. 2016 Mar 22-29; 315(12):1229-30. View in: PubMed

Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections. J Infect Dis. 2016 Mar 15; 213(6):901-3. View in: PubMed

Noninferiority Doesn't Mean Not Inferior. Clin Infect Dis. 2016 Feb 15; 62(4):525-6. View in: PubMed

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg. 2016; 11:33. View in: PubMed

Ly6G-mediated depletion of neutrophils is dependent on macrophages. Results Immunol. 2016; 6:5-7. View in: PubMed

Boronic Acid Transition State Inhibitors Active against KPC and Other Class A ß-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrob Agents Chemother. 2016; 60(3):1751-9. View in: PubMed

The Rise of Fluoroquinolone-Resistant Escherichia coli in the Community: Scarier Than We Thought. J Infect Dis. 2015 Dec 15; 212(12):1853-5. View in: PubMed

Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections. Curr Opin Microbiol. 2015 Oct; 27:57-61. View in: PubMed

Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time? Crit Care Med. Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time? Crit Care Med. 2015 Jun; 43(6):1332-4. View in: PubMed

Host Fate is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii Bacteremia. J Infect Dis. 2015 Apr 15; 211(8):1296-305. View in: PubMed

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. J Comp Eff Res. 2015 Mar; 4(2):101-14. View in: PubMed

A simple intervention to improve hospital flow from emergency department to inpatient units. JAMA Intern Med. 2015 Feb 1; 175(2):289-90. View in: PubMed

Novel Approaches Are Needed to Develop Tomorrow's Antibacterial Therapies. Am J Respir Crit Care Med. 2015 Jan 15; 191(2):135-40. View in: PubMed

Cryopreservation of virulent Acinetobacter baumannii to reduce variability of in vivo studies. BMC Microbiol. 2015; 15(1):252. View in: PubMed

Volume of fluids administered during resuscitation for severe sepsis and septic shock and the development of the acute respiratory distress syndrome. J Crit Care. 2014 Dec; 29(6):1011-5. View in: PubMed

The future of antibiotics and resistance: a tribute to a career of leadership by john bartlett. Clin Infect Dis. 2014 Sep 15; 59 Suppl 2:S71-5. View in: PubMed

Staphylococcus aureus Bacteremia at 5 US Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections. Clin Infect Dis. 2014 Sep 15; 59(6):798-807. View in: PubMed

Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther. 2014 Aug; 96(2):151-3. View in: PubMed

Transferrin iron starvation therapy for lethal bacterial and fungal infections. J Infect Dis. 2014 Jul 15; 210(2):254-64. View in: PubMed

Different tumor necrosis factor a antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice. Virulence. 2014 Jul 1; 5(5):625-9. View in: PubMed

Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun; 58(11):1571-6. View in: PubMed

Community-acquired pneumonia. N Engl J Med. 2014 May 8; 370(19):1861-2. View in: PubMed

Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia. Eur J Clin Microbiol Infect Dis. 2014 May; 33(5):845-51. View in: PubMed

The Deadly Impact of Extreme Drug Resistance in Acinetobacter baumannii*. Crit Care Med. 2014 May; 42(5):1289-91. View in: PubMed

Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use. JAMA Intern Med. 2014 Mar 1; 174(3):432-3. View in: PubMed

Impact of hospital variables on case mix index as a marker of disease severity. Popul Health Manag. 2014 Feb; 17(1):28-34. View in: PubMed

Readmissions at a public safety net hospital. PLoS One. 2014; 9(3):e91244. View in: PubMed

The future of antibiotics. Crit Care. 2014; 18(3):228. View in: PubMed

The value of single-pathogen antibacterial agents. Nat Rev Drug Discov. 2013 Dec; 12(12):963. View in: PubMed

The FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013 Oct; 57(10):4605-7. View in: PubMed

"Airborne assault": a new dimension in Acinetobacter baumannii transmission*. Crit Care Med. 2013 Aug; 41(8):2042-4. View in: PubMed

Capturing the diagnosis: an internal medicine education program to improve documentation. Am J Med. 2013 Aug; 126(8):739-743. e1. View in: PubMed

End points in trials of treatments for skin infections. JAMA. 2013 May 22; 309(20):2091-2. View in: PubMed

Seven ways to preserve the miracle of antibiotics. Clin Infect Dis. 2013 May; 56(10):1445-50. View in: PubMed

Change in intern calls at night after a work hour restriction process change. JAMA Intern Med. 2013 Apr 22; 173(8):707-9; discussion 663. View in: PubMed

The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013 Mar; 81(3):915-22. View in: PubMed

The future of antibiotics and resistance. N Engl J Med. 2013 Jan 24; 368(4):299-302. View in: PubMed

Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine. 2013 Jan 2; 31(2):313-8. View in: PubMed

Routine CSF analysis in coccidioidomycosis is not required. PLoS One. 2013; 8(5):e64249. View in: PubMed

On the exoneration of Dr. William H. Stewart: debunking an urban legend. Infect Dis Poverty. 2013; 2(1):3. View in: PubMed

Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS One. 2013; 8(7):e69508. View in: PubMed

Overcoming the challenges to developing new antibiotics. Curr Opin Pharmacol. 2012 Oct; 12(5):522-6. View in: PubMed

Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012 Aug; 50(6):611-8. View in: PubMed

Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother. 2012 Jun; 67(6):1439-45. View in: PubMed

Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin Infect Dis. 2012 Apr; 54 Suppl 3:S229-32. View in: PubMed

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012 Mar; 67(3):715-22. View in: PubMed

Development of a vaccine against Staphylococcus aureus. Semin Immunopathol. 2012 Mar; 34(2):335-48. View in: PubMed

Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis. 2012 Feb 15; 54(4):560-7. View in: PubMed

Pathogenesis of mucormycosis. Clin Infect Dis. 2012 Feb; 54 Suppl 1:S16-22. View in: PubMed

Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol (N Y). 2012 Feb; 8(2):140-2. View in: PubMed

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov. 2012 Feb; 11(2):168. View in: PubMed

How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clin Infect Dis. 2012 Feb; 54 Suppl 1:S67-72. View in: PubMed

Future directions in mucormycosis research. Clin Infect Dis. 2012 Feb; 54 Suppl 1:S79-85. View in: PubMed

Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012 Feb 1; 54(3):393-407. View in: PubMed

Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis. 2012 Feb; 54 Suppl 1:S73-8. View in: PubMed

Luminescent-activated transfected killer cells to monitor leukocyte trafficking during systemic bacterial and fungal infection. J Infect Dis. 2012 Jan 15; 205(2):337-47. View in: PubMed

Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One. 2012; 7(1):e29446. View in: PubMed

A controlled investigation of optimal internal medicine ward team structure at a teaching hospital. PLoS One. 2012; 7(4):e35576. View in: PubMed

Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio. 2012; 3(5). View in: PubMed

Acute bacterial skin and skin structure infection trials: the bad is the enemy of the good. Clin Infect Dis. 2011 Dec; 53(12):1308-9; author reply 1309-10. View in: PubMed

Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol. 2011 Nov; 49(11):3849-54. View in: PubMed

The antibiotic crisis: can we reverse 65 years of failed stewardship? Arch Intern Med. The antibiotic crisis: can we reverse 65 years of failed stewardship? Arch Intern Med. 2011 Jun 27; 171(12):1080-1. View in: PubMed

Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011 May; 52 Suppl 5:S397-428. View in: PubMed

Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery. Infect Control Hosp Epidemiol. 2011 Apr; 32(4):342-50. View in: PubMed

Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother. 2011 Apr; 55(4):1768-70. View in: PubMed

To treat or not to treat: adjunctive antibiotics for uncomplicated abscesses. Ann Emerg Med. 2011 Feb; 57(2):183-5. View in: PubMed

Vaccines for invasive fungal infections. F1000 Med Rep. 2011; 3:13. View in: PubMed

Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia. Clin Investig (Lond). 2011 Jan 1; 1(1):19-32. View in: PubMed

Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep. 2010 Nov; 12(6):423-9. View in: PubMed

Geographic differences in Medicare spending. N Engl J Med. 2010 Oct 21; 363(17):1678; author reply 1678-9. View in: PubMed

Skin and soft-tissue infections: modern evolution of an ancient problem. Clin Infect Dis. 2010 Oct 15; 51(8):904-6. View in: PubMed

A new view on development of a Staphylococcus aureus vaccine: insights from mice and men. Hum Vaccin. 2010 Oct; 6(10):857-9. View in: PubMed

The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010 Aug; 77(3):587-604. View in: PubMed

Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010 Aug 1; 51 Suppl 1:S150-70. View in: PubMed

The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010 Jun 1; 120(6):1914-24. View in: PubMed

Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis. 2010 Jun 1; 201(11):1718-28. View in: PubMed

Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. J Infect Dis. 2010 Jun 1; 201(11):1708-17. View in: PubMed

Mucormycosis, pseudallescheriasis, and other uncommon mold infections. Proc Am Thorac Soc. 2010 May; 7(3):210-5. View in: PubMed

The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother. 2010 Feb; 65(2):289-92. View in: PubMed

Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J Infect Dis. 2010 Feb 1; 201(3):473-7. View in: PubMed

Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009 Dec; 5(12):e1000703. View in: PubMed

Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis. 2009 Aug 1; 49(3):383-91. View in: PubMed

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009 Jul; 53(7):3122-5. View in: PubMed

Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009 Jun 15; 48(12):1743-51. View in: PubMed

Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. 2009 Apr; 53(4):1648-51. View in: PubMed

Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol. 2009 Apr; 55(3):293-5. View in: PubMed

Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother. 2009 Feb; 53(2):772-5. View in: PubMed

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009 Jan 1; 48(1):1-12. View in: PubMed

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? Med Mycol. Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? Med Mycol. 2009; 47(6):592-600. View in: PubMed

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis. 2008 Dec 1; 47 Suppl 3:S249-65. View in: PubMed

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008 Dec; 21(6):620-5. View in: PubMed

Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clin Infect Dis. 2008 Dec 1; 47 Suppl 3:S105-7. View in: PubMed

Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis. J Infect Dis. 2008 Oct 1; 198(7):1083-90. View in: PubMed

The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun. 2008 Oct; 76(10):4574-80. View in: PubMed

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008 Aug 1; 47(3):364-71. View in: PubMed

Dr. Stewart: mistaken or maligned? Clin Infect Dis. 2008 Jul 15; 47(2):294. View in: PubMed

Antibiotic resistance and antibiotic development. Lancet Infect Dis. 2008 Apr; 8(4):211-2; author reply 212-4. View in: PubMed

Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008 Apr; 52(4):1573-6. View in: PubMed

Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008 Apr; 52(4):1556-8. View in: PubMed

Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis. 2008 Apr 1; 197(7):967-71. View in: PubMed

Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant. Clin Vaccine Immunol. 2008 Mar; 15(3):582-4. View in: PubMed

Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans. Eukaryot Cell. 2008 Mar; 7(3):483-92. View in: PubMed

Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog. 2008 Feb 8; 4(2):e38. View in: PubMed

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008 Jan 15; 46(2):155-64. View in: PubMed

Prospects for and barriers to a fungal vaccine. Expert Opin Biol Ther. 2007 Dec; 7(12):1785-8. View in: PubMed

The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007 Sep; 117(9):2649-57. View in: PubMed

Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007 Jun; 45(4):321-46. View in: PubMed

Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development. Infection. 2007 Jun; 35(3):167-74. View in: PubMed

Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. J Leukoc Biol. 2007 Mar; 81(3):632-41. View in: PubMed

Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis. 2007 Feb 15; 44(4):471-82. View in: PubMed

Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006 Nov; 58(5):1070-3. View in: PubMed

Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006 Nov; 50(11):3968-9. View in: PubMed

Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother. 2006 Nov; 58(5):973-9. View in: PubMed

Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006 Aug; 50(8):2895-6. View in: PubMed

Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis. 2006 Jul 15; 194(2):256-60. View in: PubMed

The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun. 2006 May; 74(5):3039-41. View in: PubMed

Immunoglobulin G2 antibodies and HIV-infected long-term nonprogressors: what is the mechanism? J Infect Dis. Immunoglobulin G2 antibodies and HIV-infected long-term nonprogressors: what is the mechanism? J Infect Dis. 2006 Apr 1; 193(7):1047; author reply 1047-8. View in: PubMed

Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006 Jan 15; 42(2):244-51. View in: PubMed

The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun. 2005 Sep; 73(9):6191-3. View in: PubMed

A phagocytic cell line markedly improves survival of infected neutropenic mice. J Leukoc Biol. 2005 Aug; 78(2):338-44. View in: PubMed

Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis. 2005 Jul 15; 192(2):336-43. View in: PubMed

Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005 Jul; 18(3):556-69. View in: PubMed

Carl von Clausewitz (1780-1831) and cholera: the cause of World War II? J Med Biogr. Carl von Clausewitz (1780-1831) and cholera: the cause of World War II? J Med Biogr. 2005 May; 13(2):108-12. View in: PubMed

Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005 Apr 7; 352(14):1445-53. View in: PubMed

Spellberg B. Is computed tomography of the head useful before lumbar puncture? Clin Infect Dis. 2005 Apr 1; 40(7):1061; author reply 1062-3. View in: PubMed

Is computed tomography of the head useful before lumbar puncture? Clin Infect Dis. 2005 Apr 1; 40(7):1061; author reply 1062-3. View in: PubMed

Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun. 2005 Feb; 73(2):999-1005. View in: PubMed

Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005 Feb; 73(2):778-83. View in: PubMed

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005 Feb; 49(2):721-7. View in: PubMed

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005 Feb; 49(2):830-2. View in: PubMed

Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother. 2004 Oct; 54(4):832-5. View in: PubMed

Treatment of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections with drainage but no antibiotic therapy. Pediatr Infect Dis J. 2004 Aug; 23(8):795; author reply 795-6. View in: PubMed

Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett. 2004 Jun 1; 235(1):169-76. View in: PubMed

Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004 May 1; 38(9):1279-86. View in: PubMed

Spellberg B, Witt MD, Beck CK. Amphotericin B: is a lipid-formulation gold standard feasible? Clin Infect Dis. 2004 Jan 15; 38(2):304-5; author reply 306-7. View in: PubMed

Amphotericin B: is a lipid-formulation gold standard feasible? Clin Infect Dis. 2004 Jan 15; 38(2):304-5; author reply 306-7. View in: PubMed

Spider bites and infections caused by community-associated methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt). 2004; 5(3):321-2; author reply 322. View in: PubMed

Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003 Oct; 47(10):3343-4. View in: PubMed

Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun. 2003 Oct; 71(10):5756-64. View in: PubMed

Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis. 2003 Apr 15; 36(8):1091-3. View in: PubMed

The Pathophysiology and Treatment of Candida Sepsis. Curr Infect Dis Rep. 2002 Oct; 4(5):387-399. View in: PubMed

mtDNA disease in the primary care setting. Arch Intern Med. 2001 Nov 12; 161(20):2497-500. View in: PubMed

Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis. 2001 Jan; 32(1):76-102. View in: PubMed

The cutaneous citadel: a holistic view of skin and immunity. Life Sci. 2000 Jun 23; 67(5):477-502. View in: PubMed

Autologous bone marrow transplantation in acute leukemia. Hematol Oncol Clin North Am. 1999 Oct; 13(5):919-38. View in: PubMed

Mechanism of intravenous immune globulin therapy. N Engl J Med. 1999 Jul 1; 341(1):57-8. View in: PubMed

Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998 Oct 15; 44(8):778-83. View in: PubMed

Olanzapine-induced reversible priaprism: a case report. J Clin Psychopharmacol. 1998 Aug; 18(4):351-3. View in: PubMed

Cloning and characterization of CAD1/AAF1, a gene from Candida albicans that induces adherence to endothelial cells after expression in Saccharomyces cerevisiae. Infect Immun. 1998 May; 66(5):2078-84. View in: PubMed

Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J Clin Invest. 1997 Jan 15; 99(2):336-41. View in: PubMed

Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells. Infect Immun. 1996 Jul; 64(7):2609-17. View in: PubMed

Reduced virulence of Candida albicans PHR1 mutants. Infect Immun. 1995 Nov; 63(11):4528-30. View in: PubMed

Does real-time feedback to residents with or without attendings improve medical documentation? Hosp Pract (1995). Does real-time feedback to residents with or without attendings improve medical documentation? Hosp Pract (1995). 2014 Aug; 42(3):123-30. View in: PubMed

Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother. 1994 Sep; 38(9):2029-33. View in: PubMed

Powered bySC CTSI